SLC1A4 and hepatocellular carcinoma: Finally, drug sensitivity analysis showed that low-expression of SLC1A4 exhibited resistance to 21 and 69 drugs, a positive correction was also observed between SLC1A4 expression and drug sensitivity (Bafetinib, Dabrafenib, Hypothemycin, okadaic acid and PD-98095), suggesting that the five sensitivity drugs may be effective therapeutic strategy for HCC patients with high-expressed SLC1A4.